Avenzo gets FDA permission to proceed with Phase I/II trials of an EGFR/HER3 bispecific antibody and a CDK4 inhibitor in select solid tumors.

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

NEW YORK – CureDuchenne Ventures has made a $1 million initial investment in Entos Pharmaceuticals, supporting its development of a genetic medicine for Duchenne muscular dystrophy (DMD).

The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

The company plans to use the money to continue an ongoing global Phase II trial of the drug in several BRAF-altered tumor types.

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.

NEW YORK – Sarepta Therapeutics on Wednesday said that the UK's Medicines & Healthcare Products Regulatory Agency has lifted the clinical hold on a Phase III study of its Duchenne muscular dystrophy ...

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

NEW YORK – The first patient with an advanced, MTAP-deleted solid tumor has received Tango Therapeutics' PRMT5 inhibitor TNG456 in a Phase I/II trial, the company said Wednesday. The Boston-based firm ...

NEW YORK – Fractyl Health has submitted the first module of a clinical trial application with European regulators seeking to begin a first-in-human study of its investigational gene therapy for type 2 ...